Company Description
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally.
It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing.
It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases.
The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery.
The company sells its products and services through direct sales forces and independent distributors.
Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
| Country | Canada |
| Founded | 1853 |
| IPO Date | May 6, 2022 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 13,500 |
| CEO | Brenton Saunders |
Contact Details
Address: 520 Applewood Crescent Vaughan, ON L4K 4B4 Canada | |
| Phone | 905-695-7700 |
| Website | bausch.com |
Stock Details
| Ticker Symbol | BLCO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001860742 |
| CUSIP Number | 071705107 |
| ISIN Number | CA0717051076 |
| SIC Code | 3851 |
Key Executives
| Name | Position |
|---|---|
| Brenton L. Saunders J.D. | Chief Executive Officer and Chairman |
| Osama A. Eldessouky | Executive Vice President and Chief Financial Officer |
| A. Robert D. Bailey | Executive Vice President and Chief Legal Officer |
| Dr. Yehia Hashad M.D., Ph.D. | Executive Vice President of Research and Development and Chief Medical officer |
| Andrew J. Stewart | President of Global Pharmaceuticals and International Consumer |
| Alan Waterhouse CPFA, MBA | Executive Vice President and Chief Supply Chain and Operations Officer |
| Frederick J. Munsch | Senior Vice President, Controller and Chief Accounting Officer |
| Jonathon L. Kellerman | Chief Compliance Officer |
| T.J. Crawford | Chief Communications Officer |
| Dr. Manisha A. Narasimhan Ph.D. | Chief Corporate Development and Digital Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 23, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| May 30, 2025 | SD | Form - SD |
| May 21, 2025 | 8-K | Current Report |
| May 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2025 | 8-K | Current Report |